Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Phase III Trial of Atezolizumab in Early Breast Cancer
2017-002771-25Phase 3Active
- Sponsor
- NSABP Foundation
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atezolizumab in breast cancer, sponsored by NSABP Foundation. Primary endpoint: Event-free survival. Started Nov 2017; status: active.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-002771-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002771-25.